Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Biotechnol Lett ; 40(6): 989-998, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29619744

RESUMO

OBJECTIVE: To compare four enzymatic protocols for mesenchymal stem cells (MSCs) isolation from amniotic (A-MSC) and chorionic (C-MSC) membranes, umbilical cord (UC-MSC) and placental decidua (D-MSC) in order to define a robust, practical and low-cost protocol for each tissue. RESULTS: A-MSCs and UC-MSCs could be isolated from all samples using trypsin/collagenase-based protocols; C-MSCs could be isolated from all samples with collagenase- and trypsin/collagenase-based protocols; D-MSCs were isolated from all samples exclusively with a collagenase-based protocol. CONCLUSIONS: The trypsin-only protocol was least efficient; the collagenase-only protocol was best for C-MSCs and D-MSCs; the combination of trypsin and collagenase was best for UC-MSCs and none of tested protocols was adequate for A-MSCs isolation.


Assuntos
Separação Celular/métodos , Membranas Extraembrionárias/citologia , Células-Tronco Mesenquimais/citologia , Placenta/citologia , Cordão Umbilical/citologia , Proliferação de Células , Células Cultivadas , Colagenases , Feminino , Humanos , Cinética , Gravidez , Tripsina
2.
Int J Lab Hematol ; 37(2): 259-64, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25066534

RESUMO

INTRODUCTION: Engraftment is a critical milestone of the hematopoietic stem cell transplantation (HSCT) process. The immature platelet fraction (IPF) and immature reticulocyte fraction (IRF) are considered early indicators of bone marrow recovery. The objective of this study was to assess these parameters as predictors of HSCT engraftment. METHODS: Neutrophil and platelet engraftment were defined as the first of three consecutive days with an absolute neutrophil count >0.5 × 10(9) /L or platelet count >20 × 10(9) /L, respectively. The IRF cutoff was 12%. Two IPF cutoffs were used: >6.2% and >10%. RESULTS: The study sample comprised 44 patients, of whom 24 had undergone autologous HSCT and 20 had undergone allogeneic HSCT. Absolute neutrophil counts >0.5 × 10(9) /L were preceded by IRF >12% in 86% of patients (38 of 44). Platelet counts >20 × 10(9) /L were preceded by an IPF >6.2% in 90% of patients (37 of 41) and by an IPF >10% in 63% of patients (26 of 41). CONCLUSION: The results show that IRF and IPF are engraftment predictors. Peak in IPF was observed before rise in platelet count, while IRF rises before absolute neutrophil count (ANC) and persists increased. This indicates that IRF and IPF can be considered as new tools for hematopoietic assessment after HSCT.


Assuntos
Sobrevivência de Enxerto , Transplante de Células-Tronco Hematopoéticas , Contagem de Plaquetas , Contagem de Reticulócitos , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Neutrófilos , Prognóstico , Transplante Autólogo , Transplante Homólogo , Adulto Jovem
3.
Epidemiol Infect ; 141(4): 875-9, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22691688

RESUMO

Invasive fungal diseases have emerged as important causes of morbidity and mortality in haematological patients. In this study air samples were collected in two haematopoietic stem cell transplantation (HSCT) units, in which distinct air-control systems were in place. In hospital 1 no high-efficiency particulate air (HEPA) filter was available whereas in hospital 2 HSCT rooms were equipped with HEPA filters, with positive air pressure in relation to the corridor. A total of 117 samples from rooms, toilets and corridors were obtained during December 2009 to January 2011, using a six-stage Andersen sampler. In both hospitals, the concentration of potentially pathogenic fungi in the air was reduced in patients' rooms compared to corridors (P < 0·0001). Despite the presence of a HEPA filter in hospital 2, rooms in both hospitals showed similar concentrations of potentially pathogenic fungi (P = 0·714). These findings may be explained by the implementation of additional protective measures in hospital 1, emphasizing the importance of such measures in protected environments.


Assuntos
Microbiologia do Ar , Aspergillus/isolamento & purificação , Fungos/isolamento & purificação , Transplante de Células-Tronco Hematopoéticas , Unidades Hospitalares , Controle de Infecções , Esporos Fúngicos/isolamento & purificação , Filtros de Ar , Movimentos do Ar , Infecção Hospitalar/prevenção & controle , Humanos , Micoses/prevenção & controle , Quartos de Pacientes
4.
Cell Immunol ; 265(2): 127-32, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20727519

RESUMO

CD55 and CD59 are glycosylphosphatidylinositol-anchored proteins with complement inhibitory properties. CD55 inhibits the formation of C3 convertases, and CD59 prevents the terminal polymerisation of the membrane attack complex. It has been reported that SLE patients seems to have an acquired deficiency of these proteins associated with secondary autoimmune haemolytic anaemia and lymphopenia. The aim of this study was to evaluate the presence of altered CD55 and CD59 expression on peripheral blood cells from SLE patients. Flow cytometric analyses were performed on red and white blood cells from 23 SLE patients and 23 healthy controls. We observed more CD55- and CD59-lymphocytes (p=0.005 and p=0.019, respectively), and CD59-granulocytes (p=0.045) in SLE patients than in controls. These results suggest there is an altered pattern of CD55 and CD59 expression on the peripheral blood cells of SLE patients, and it may play a role in the cytopenias in these patients.


Assuntos
Antígenos CD55/sangue , Antígenos CD59/sangue , Lúpus Eritematoso Sistêmico/sangue , Adulto , Anemia Hemolítica Autoimune/sangue , Anemia Hemolítica Autoimune/etiologia , Contagem de Células Sanguíneas , Células Sanguíneas/imunologia , Células Sanguíneas/patologia , Feminino , Citometria de Fluxo , Glicosilfosfatidilinositóis/sangue , Glicosilfosfatidilinositóis/imunologia , Humanos , Imunofenotipagem , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/imunologia , Linfopenia/sangue , Linfopenia/etiologia , Masculino , Pessoa de Meia-Idade , Adulto Jovem
5.
Tissue Antigens ; 74(4): 308-13, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19775370

RESUMO

Despite its well known monogenic etiopathogenesis, sickle cell disease (SCD) is characterized by a striking variability of clinical presentation. There is growing evidence that genetic factors may be involved in this variability. Human leukocyte antigen (HLA)-G is a non-classical HLA molecule which was shown to be expressed at sites of inflammation and in inflammatory diseases. Besides its large and highly polymorphic promoter region, the 3' UTR region seems also to play an important role on regulating HLA-G expression. We investigated the influence of the 14 pb (rs1704) and the +3142 (rs1063320) HLA-G polymorphisms in 93 SCD patients in order to evaluate its potential role on clinical parameters. Twenty-one patients presented an HCV infection. Among all SCD patients 16 (22.2%) were homozygous for the +3142C genotype, none of them hepatitis C (HCV) positive. Controlling for blood transfusions in the last year, the C allele represented a dose dependent protection effect for HCV infection (PR = 0.41; 95% CI: 0.24-0.71). The +3142C allele was also underrepresented among patients with history of respiratory-tract infections. Our results support a role of the +3142 polymorphism in the susceptibility to infections, in particular to HCV infection, and suggest a possible interference of the HLA-G molecule in the response to infections, among SCD patients.


Assuntos
Anemia Falciforme/genética , Anemia Falciforme/virologia , Antígenos HLA/genética , Hepacivirus/genética , Hepatite C/genética , Antígenos de Histocompatibilidade Classe I/genética , Polimorfismo Genético/genética , Adulto , Anemia Falciforme/imunologia , Estudos de Casos e Controles , Suscetibilidade a Doenças , Feminino , Antígenos HLA-G , Hepatite C/complicações , Hepatite C/imunologia , Humanos , Masculino , Adulto Jovem
6.
Bone Marrow Transplant ; 43(12): 953-7, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19363530

RESUMO

Post-BMT subjects have an increased bone fracture risk. Additionally, several factors were associated with osteopenia and osteoporosis in these individuals. We aimed to identify other factors associated with osteopenia and osteoporosis in allogeneic post-BMT subjects. We conducted a cross-sectional study with 47 allogeneic post- BMT subjects. Serum 25-hydroxyvitamin D (25(OH)D), parathyroid hormone, ferritin, vitamin B(12), insulin, glucose, cholesterol and triglyceride levels were measured. Insulin resistance and secretion were estimated through the homeostatic model assessment for insulin resistance (HOMA-IR) and homeostatic model assessment for beta-cell function (HOMA-B), respectively. A bone densitometry (BMD) was also obtained. The median time after BMT was 47.7 (12-115) months. Osteoporosis was identified in 17.0% of the subjects and osteopenia in 19.7%. The mean serum ferritin (P=0.002), insulin (P<0.0001), glucose (P=0.003) and triglyceride (P=0.018) levels were higher in individuals with osteopenia/osteoporosis. HOMA-IR (P<0.0001) and HOMA-B (P<0.0001) were increased in post-BMT subjects with osteopenia/osteoporosis. There was no other factor associated with the outcome. After adjustments ferritin, serum 25(OH)D and HOMA-IR remained independently associated with osteopenia/osteoporosis; however triglycerides no longer were. In conclusion, in the present study, low serum 25(OH)D levels, high serum ferritin levels and insulin resistance were associated with osteopenia/osteoporosis in post-BMT subjects.


Assuntos
Densidade Óssea , Transplante de Medula Óssea/efeitos adversos , Resistência à Insulina , Adolescente , Adulto , Doenças Ósseas Metabólicas/diagnóstico , Doenças Ósseas Metabólicas/terapia , Estudos Transversais , Feminino , Ferritinas/sangue , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Osteoporose/diagnóstico , Osteoporose/terapia , Fatores de Risco , Transplante Homólogo , Resultado do Tratamento , Vitamina D/análogos & derivados , Vitamina D/sangue
7.
Med Hypotheses ; 64(1): 174-6, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15533637

RESUMO

Although the molecular basis of sickle cell disease (SCD) is well established, the wide variability in clinical manifestations still puzzles haematologists and clinicians. Recently, SCD started to be considered by different groups as a chronic inflammatory condition, where the inflammatory tendency of each individual could drive more or less severe clinical features. Here we describe a haemoglobin SC disease patient (heterozygous to both HbS and HbC variants) that experienced several vaso-occlusive crises before underwent a successful kidney transplantation. Since then (16 years ago), she is on uninterruped immunosuppressive therapy, and do not experienced any severe vaso-occlusive crisis. Considering SCD associated morbidity as a result of exacerbated immune responses, we suggest that the immunosuppressive therapy directed to the kidney graft maintenance is actually also helping in the control of the chronic inflammatory responses associated to SCD.


Assuntos
Rejeição de Enxerto/prevenção & controle , Doença da Hemoglobina SC/tratamento farmacológico , Doença da Hemoglobina SC/imunologia , Imunossupressores/administração & dosagem , Modelos Imunológicos , Doenças Vasculares/imunologia , Doenças Vasculares/prevenção & controle , Adulto , Feminino , Rejeição de Enxerto/etiologia , Doença da Hemoglobina SC/complicações , Humanos , Falência Renal Crônica/etiologia , Falência Renal Crônica/cirurgia , Transplante de Rim/efeitos adversos , Resultado do Tratamento , Doenças Vasculares/etiologia
8.
Acta Haematol ; 107(4): 203-7, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12053147

RESUMO

Reports on treatment outcomes in adults with acute lymphoblastic leukemia (ALL) in Brazil are sparse. To evaluate the outcome of patients with ALL managed by the public healthcare system, we studied 42 adults treated from 1990 to 1997 in the Division of Hematology at Hospital de Clínicas, Porto Alegre, Brazil. Of these patients, 14/42 were females and their median age at diagnosis was 26 (17-64) years. The diagnosis of ALL was based on cytological examination of marrow smears, and immunophenotypic and cytogenetic studies, when available. Fifty percent of the patients expressed CD10, 30% were CD10 negative and CD19 positive and 20% expressed T markers. Philadelphia chromosome was found in 4 (7.14%). The chemotherapy protocol was adapted from the German Multicenter ALL (GMALL) 02-84 protocol. The complete remission rate was 93% and the overall survival at 5 years was 41%. No particular risk factor was identified in our series. These results are comparable to the findings of other international studies.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adolescente , Adulto , Antígenos CD19/análise , Brasil , Países em Desenvolvimento , Intervalo Livre de Doença , Feminino , Humanos , Imunofenotipagem , Tábuas de Vida , Masculino , Pessoa de Meia-Idade , Neprilisina/análise , Cromossomo Filadélfia , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Indução de Remissão , Estudos Retrospectivos , Análise de Sobrevida , Taxa de Sobrevida , Resultado do Tratamento
10.
Br J Haematol ; 93(2): 375-85, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8639431

RESUMO

Activated natural killer (A-NK) cells, a subset of CD56(dim)CD3- lymphocytes, are obtained from PBMC of normal donors by adherence to plastic and culture in the presence of IL2. In this study we tested the feasibility of generating A-NK cells in patients with Ph+ chronic myeloid leukaemia (CML). Cultures obtained from patients with early chronic phase (ECP; n=7) contained a mean (+/-SD) of83 +/- 7% of CD3- cells, and those from patients with advanced chronic phase (ACP; n=7) contained 27+/-33% CD56+CD3- cells. In three patients with leukaemia in a blastic phase (BP) it was only possible to obtain one culture enriched in CD56+CD3- cells (81%). Cellular aggregates of myeloid cells and large granular lymphocytes were observed in early A-NK cell cultures. Paired freshly-adherent and cultured A-NK cells were tested for the presence of BCR/abl mRNA by RT-PCR. The BCR/abl+ cells were detected in all 12 preparations of the freshly adherent A-NK cells tested. In 6/12 the BCR/abl+ cells were no longer detectable by RT-PCR on day 14 of culture. Both proliferation and antileukaemic cytotoxicity were significantly higher (P=0.002 and P=0.029, respectively) in the BCR/abl- cultures than those in the six BCR/abl+ cultures. 5/6 BCR/abl- cultures were highly enriched in A-NK cells on day 14, and 1/6 contained predominantly CD56+CD3+ cells. Only 2/6 BCR/abl + cultures were enriched in A-NK cells on day 14, but they had poor cytotoxicity and a low proliferative index. Myeloid cells (CD33+) were more frequently detected in the BCR/abl+ than BCR/abl- A-NK cell cultures (P=0.028). These observations suggest that: (1) populations of benign A-NK cells can be generated from the peripheral blood of CML patients; (2) the ability to generate A-NK cells is impaired in patients with advanced CML; and (3) the ability to generate A-NK cells with antileukaemic activity correlates with the disappearance of BCR/abl+ cells from these cultures.


Assuntos
Células Matadoras Ativadas por Linfocina/imunologia , Células Matadoras Naturais/imunologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/imunologia , Antígenos CD/genética , Sequência de Bases , Divisão Celular , Citotoxicidade Imunológica , Proteínas de Fusão bcr-abl/genética , Rearranjo Gênico , Humanos , Células Matadoras Ativadas por Linfocina/patologia , Células Matadoras Naturais/patologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Ativação Linfocitária , Dados de Sequência Molecular , Fenótipo , Células Tumorais Cultivadas
11.
J Hematother ; 4(4): 269-79, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7489141

RESUMO

The success of chemotherapy in patients with leukemia whose marrow appears to be replaced by leukemia cells must be due to the persistence of normal stem cells. In this normal population are the progenitors of the cells of the immune system. Natural killer (NK) cells originate in the bone marrow. On maturation and activation with interleukin 2 (IL-2) or other cytokines, NK cells develop cytotoxic activity against a variety of leukemic blasts, including those from patients with chronic myeloid leukemia (CML). In the past few years, bone marrow transplantation (BMT) and alpha-interferon (IFN-alpha) have proved to be the most promising therapies for the treatment of CML. In both these therapies, NK cells may play a prominent role. In this article, we discuss the antitumor/antileukemia activity of human NK cells, the presence of benign NK cell precursors in the different stages of CML, the role of NK cells in BMT and IFN-alpha treatment, and the potential therapeutic applications of NK cells in patients with hematologic malignancies.


Assuntos
Transplante de Medula Óssea , Citocinas/imunologia , Imunoterapia , Células Matadoras Naturais/imunologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/imunologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Medula Óssea/patologia , Citotoxicidade Imunológica , Humanos , Interferon Tipo I/uso terapêutico , Interleucina-2/imunologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Proteínas Recombinantes
12.
Br J Haematol ; 89(4): 712-8, 1995 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7772507

RESUMO

Bispecific antibodies recognizing tumour-associated antigens and trigger molecules expressed on immune effector cells have been shown to redirect cytotoxicity of several types of peripheral blood cells against relevant tumour targets. Among various effector cells, natural killer (NK) cells appear to play a role in defence against leukaemia. Here we report the successful chemical conjugation of monoclonal antibodies to CD33 and CD16 to create a bispecific antibody (BsAb 251 x 3G8). This bispecific antibody is capable of augmenting the killing of otherwise resistant leukaemia cells by peripheral blood lymphocytes (PBL), purified resting NK (R-NK) cells, and activated NK (A-NK) cells. BsAb 251 x 3G8 may play a role in the therapy of acute myeloid leukaemia (AML) through redirecting the cytotoxic activity of endogenous or adoptively transferred NK cells.


Assuntos
Anticorpos Biespecíficos/fisiologia , Antígenos CD/imunologia , Antígenos de Diferenciação Mielomonocítica/imunologia , Células Matadoras Naturais/imunologia , Leucemia Mieloide/imunologia , Receptores de IgG/imunologia , Doença Aguda , Citotoxicidade Imunológica , Relação Dose-Resposta Imunológica , Humanos , Leucemia Mieloide/terapia , Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA